INTRODUCTION
Neuropilins (NRPs) are transmembrane glycoproteins that play an important role in various biological processes, including axonal guidance, angiogenesis, tumorigenesis, and the immunological response. [1] [2] [3] [4] NRPs have been characterized as coreceptors for two unrelated families of extracellular secreted ligands − class III semaphorins and several members of the vascular endothelial growth factor (VEGF) family, the main regulators of blood and lymphatic vessel growth. 5 NRP acts in conjunction with membrane-associated signal transducers, such as the VEGF receptor tyrosine kinases (VEGFR-1, -2 and -3) 6, 7 and plexins, the transmembrane receptors of the semaphorin family. 8 In higher eukaryotes, two neuropilin genes, NRP1 and NRP2, have been identified. 9 They code for proteins displaying about 44%
amino-acid sequence identity, with a similar domain structure. 10 Both NRP1 and NRP2
contain a large extracellular region and a short cytoplasmic tail of about 40 amino acids, lacking any enzymatic activity. The extracellular region of neuropilins contains five different structural domains − two CUB motifs, a1 and a2, homologous to complement components C1r/C1s, two coagulation factor V/VIII homology domains b1 and b2, and one c domain (MAM, homologous to meprin, A5, µ). 11 The high-affinity binding site for VEGF-A 165 has been localized to the b1 and b2 domains of NRP1 12, 13 and NRP2, 14 whereas the binding of semaphorins requires both the a1a2 and b1b2 repeats.
12
NRP1 and NRP2 interact selectively with different members of the VEGF and semaphorin families and have non-overlapping expression patterns. Thus, among the VEGF members, NRP1 binds VEGF-A 165 , VEGF-B, VEGF-E and placental growth factor (PlGF), whereas NRP2 binds VEGF-A 165 , VEGF-A 145 , VEGF-C and PlGF. 15 The non heparin-binding isoforms of VEGF, such as VEGF-A 121 , have long been considered unable to interact with NRPs. Current evidence suggests, however, that VEGF-A 121 does bind NRP1, via the Conly.
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in the venous and lymphatic endothelial cells. 20 Genetic studies in mouse have shown that both the overexpression of NRP1 21 and the targeted inactivation of the NRP1 gene 22, 23 are lethal, provoking, in addition to neuronal defects, disorganization of the vascular network and defects in heart development. Inactivation of the NRP2 gene has less severe consequences, limited to defects in the formation of small lymphatic vessels and capillaries. 24 However, mice in which both neuropilin genes have been invalidated had a very severe vascular phenotype and died after embryonic day 8.5. 25 Thus, neuropilins are essential for vasculogenesis, angiogenesis and lymphangiogenesis.
The role of NRPs in the control of vascular function has been attributed principally to their ability to regulate the activities of VEGF on endothelium. In endothelial cells, NRPs are thought to increase signaling through the VEGFRs by ensuring the optimal presentation of VEGF and by stabilizing VEGF/VEGFR complexes. Thus, the interaction of VEGF-A 165 with NRP1 is required for stable binding of VEGF-A 165 to VEGFR-2, full activation of VEGFR-2
and downstream signaling and biological responses. 17, 26 Similarly, the interaction of VEGF-A or VEGF-C with NRP2 increases the VEGFR-2 phosphorylation threshold and promotes the endothelial cell survival and motility induced by VEGF-A and VEGF-C. 7 In contrast, disruption of the NRP1/VEGF-A interaction with a highly specific blocking antibody reduces VEGFR-2 activation and signaling, inhibiting angiogenesis and vascular remodeling in a mouse tumor model. 27 Both NRP1 and NRP2 enhance the affinity of VEGF-A 121 binding to VEGFR-2 and increase VEGF-A 121 -induced VEGFR-2 phosphorylation, thereby regulating proliferation, migration and sprouting of endothelial cells. 19, 28 Evidence has recently been obtained to suggest that, in addition to VEGF, a number of heparin-binding growth factors interact with NRPs. 29 Some of these factors, including only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From hepatocyte growth factor (HGF) and several members of the fibroblast growth factor (FGF) family, have been characterized as potent proangiogenic cytokines. 30, 31 At least for FGF-2, the interaction with NRP1 is thought to be physiologically relevant, as NRP1 was found to enhance the growth stimulatory activity of FGF-2 on endothelial cells. 29 Two recent studies have demonstrated a novel role for NRP1 in tumor progression through enhancement of the autocrine HGF/c-met loop. 32, 33 These findings suggest that NRP1 may also act as functional coreceptor for HGF.
HGF is a pleiotropic cytokine that acts on target cells by binding to the c-met receptor. 11 The mature factor is a heterodimer of α-and β-chains. 34, 35 The α-chain is primarily involved in the interaction of HGF with the c-met receptor and heparin. [36] [37] [38] After binding, HGF induces the phosphorylation of c-met, resulting in the recruitment of several downstream signaling transducers, including Grb2, Gab1, STAT3, Shc, SHIP-1, Src, and phosphatidylinositol-3 kinase. 39 These events lead to privileged stimulation of the Rasextracellular signal-regulated kinase (ERK) cascade and activation of other members of the mitogen-activated protein kinase (MAPK) family. c-met is expressed in most tissues and HGF/c-met signaling is essential for the development and regeneration of several organs and systems, 40 and for the malignant progression of various cancers. 39, 41 HGF is also a potent stimulator of angiogenesis. 30 Endothelial cells undergoing angiogenesis have the highest levels of c-met receptor expression. 42 HGF signals through c-met to regulate endothelial cell survival, proliferation, migration, matrix deposition and degradation, together with the formation of capillary-like structures. In vivo, HGF stimulates angiogenesis in several animal models of ischemia, with an efficiency similar to, or even greater than that of VEGF-A 165 . [43] [44] [45] The role of NRPs in the regulation of HGF function on endothelial cells has yet to be explored. To do this, we first analyzed whether HGF could interact with NRP2 in addition to NRP1. We also carried out a structure-function analysis, to map the NRP-binding region only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From within HGF. We compared the NRP-binding properties of full-length HGF with those of recombinant proteins corresponding to the five HGF α-chain structural domains − the Nterminal domain (N) and four kringle domains 46 . We then used an RNA interference approach and blocking anti-NRP antibodies to explore the role of NRPs in VEGF-A 165 -and HGFinduced signaling and cellular responses in human umbilical vein endothelial cells (HUVEC).
Finally, we analyzed the effect of a blocking anti-NRP1 antibody on HGF-induced angiogenesis in a mouse Matrigel model. kringle domains 1 to 4) were produced and purified as previously described. 46 A goat anti- 
MATERIALS AND METHODS

Approval
Cells
HUVEC were isolated from human umbilical veins by collagenase digestion and were cultured in M199 medium supplemented with 15 mM HEPES, 2 mM glutamine, 50 IU/ml penicillin, 50 µg/ml streptomycin, 2.5 µg/ml amphotericin B, 15% (v/v) fetal bovine serum (FBS), 5% (v/v) human serum, and 2 ng/ml FGF-2. Cells were grown in gelatin-coated flasks at 37°C in an atmosphere containing 5% CO 2 . Before stimulation, HUVEC were starved overnight in serum-free EBM medium. All subsequent steps were performed in this medium, unless otherwise stated. All experiments were carried out with cells from passages 2 and 3. only.
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Immunoprecipitation and western blot analysis
After treatment, cells were lysed in 50 mM Tris-HCl, pH 8.0, containing 100 mM NaCl, 1%
(v/v) Triton X-100, 0.5% (v/v) NP40, 5 mM EDTA, 1 mM PMSF, 1 µg/ml leupeptin, 1 µg/ml aprotinin, 1 mM sodium orthovanadate, 40 mM β-glycerophosphate, 50 mM NaF and 100 µM phenylarsine oxide. Insoluble material was removed by centrifugation at 14,000g for 10 min at 4°C. The protein concentration in the supernatant was determined using the BCA Protein Assay Reagent (Pierce). For immunoprecipitation, 800 µg of protein was incubated with 5 µg of anti c-met antibody overnight at 4°C, and for a further 2 h with protein A-Sepharose beads.
The antigen-antibody complexes were eluted with NuPAGE LDS sample buffer (Invitrogen), separated by electrophoresis in 4 to 12% NuPAGE gels (Invitrogen), and transferred to nitrocellulose membranes. Non-specific binding was blocked by incubating the membranes with PBS containing 5% non fat milk powder for 1 h at room temperature. Membranes were probed overnight at 4°C with specific primary antibody, and then with peroxidase-conjugated secondary antibody. Antigen-antibody complexes were detected with the SuperSignal West Pico chemiluminescent substrate (Pierce). Bands were visualized with an LAS-3000 Luminescent Image Analyzer (Fujifilm, Japan) and quantified with Multi Gauge 4.0 software (Fujifilm).
DNA biosynthesis assays
HUVEC were seeded in 24-well plates at a density of 15,000 cells per well, in complete medium. After one day of culture, the cells were starved by incubation for 24 hours in serumfree EBM medium. They were then stimulated by incubation for a further 20 hours with HGF (2 to 10 ng/ml) or VEGF-A 165 (10 ng/ml) in the presence of anti-NRP1 or non-immune IgG (20 µg/ml). Cells were incubated for the last 16 at 37°C in an atmosphere containing 5% CO 2 , and, after the times indicated, the number of cells that had migrated to the lower surface of the filters was evaluated by fluorescence measurements using a Wallac 1420 multilabel counter (Perkin Elmer, Turku, Finland). Each experiment (n=3) was performed in triplicate.
In vivo assessment of angiogenesis using the Matrigel plug assay
Animals were cared for in accordance with the guidelines of the European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes, and the study protocol was approved by the local ethics committee. Briefly, Matrigel was mixed with HGF (300 ng/ml), heparin (20 IU/ml), anti-NRP1 or an isotype control IgG (20 µg/ml) and the resulting mixture was injected subcutaneously (0.5 ml) into both flanks of seven-week-old male C57BL/6 mice (Harlan, France) under isoflurane/oxygen anesthesia. The animals were sacrificed eight days later, and the Matrigel plugs were removed, weighed and photographed.
For each mouse, one plug was embedded in paraffin, sectioned and processed for haematoxylin-eosin-safran (HES) staining and immunohistochemistry analysis. The second only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From plug was homogenized in PBS using an Ultra-Turrax T25 homogenizer (Bioblock, Illkirch, France). Debris was removed by centrifugation, the supernatant was mixed with Sulfolyzer (Sysmex, Roche) and its hemoglobin content was assessed by determining absorbance at 550 nm. The standard curve for hemoglobin quantification was generated with purified rat hemoglobin (Sigma) treated in the same way as the samples. Hemoglobin concentration values were normalized according to plug weight, using a correction index calculated as the ratio of the weight of plug to the weight of the smallest plug. 
RESULTS
NRP1 and NRP2 bind HGF
To determine whether NRP1 and NRP2 can bind HGF, we used an ELISA-based approach. We first analyzed the impact of NRP1 knockdown on HGF function in HUVEC. Offtarget effects were minimized using three siRNA targeting different sequences of NRP1, and three control siRNAs. The transfection of HUVEC with any of the three NRP1 siRNAs resulted in a large decrease in NRP1 protein levels, down to the detection limit for western blotting ( Figure 3A) . In HUVEC transfected with NRP1 siRNA, the levels of c-met phosphorylation induced by HGF were 40% lower than in HUVEC transfected with control siRNA ( Figure 3B ). Accordingly, NRP1 knockdown in HUVEC decreased the activation of several signaling pathways downstream from c-met. In HUVEC transfected with the various NRP1 siRNAs, HGF-induced ERK2 activation was 50% lower than in HUVEC transfected with any of the control siRNAs ( Figure 3C ). As expected, VEGF-A 165 -induced ERK2 activation was also reduced in these cells. Similarly, p38 kinase and Akt (Ser473) phosphorylation induced by HGF or VEGF-A 165 was 60 to 50% lower in HUVEC transfected only.
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We further transfected HUVEC with NRP2 siRNA. In these conditions, NRP2 protein levels were very much lower than in HUVEC transfected with control siRNA ( Figure 4A ). In HUVEC transfected with NRP2 siRNA, the phosphorylation of c-met and activation of ERK2 following stimulation with HGF were reduced (by 60% and 70%, Figure 4B and C, respectively). As expected, 7 VEGF-A 165 -induced ERK2 activation was also reduced in these cells ( Figure 4D ). The transfection of HUVEC with both NRP1 and NRP2 siRNAs led to the 
NRP1 and NRP2 enhance VEGF-A 165 -and HGF-induced cellular responses in HUVEC
During the first few hours following transfection, NRP1 siRNA had no significant effect on HUVEC morphology or viability. However, consistent with reported data, 48,49 the prolonged (more than 24 hours) inhibition of NRP1 expression was harmful for HUVEC, decreasing cell adhesion and survival. Note that the short half-lives of the non modified or non stabilized siRNAs in vivo render them unsatisfactory for animal studies. We therefore used a blocking only.
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We first confirmed, by western blot analysis, the blocking activity of this antibody in an ERK1/2 activation assay: VEGF-A 165 -and HGF-induced ERK2 activation was decreased by 30% in the presence of 20 µg/ml anti-NRP1 IgG ( Figure 5A ). As ERK1/2 has been shown to be essential for endothelial cell proliferation, 50 we used a [ A 165 -induced proliferation (by 47% and 40%, respectively), whereas non immune IgG had no effect ( Figure 5B ). We also checked that non immune IgG had no effect on cell proliferation when used alone (data not shown).
VEGF-A 165 and HGF-induced activation of p38 kinase, a key kinase for HUVEC migration, 51 was decreased by NRP1 knockdown. We analyzed the involvement of 
NRP1 is essential for HGF-induced angiogenesis in vivo
To study the role of NRP1 in the regulation of HGF function in vivo, we analyzed the effect of blocking anti-NRP1 antibody on HGF-induced angiogenesis in Matrigel plugs formed in mice after the subcutaneous injection of Matrigel. Neovascularization was induced by mixing Matrigel with angiogenic cocktail containing 300 ng/ml of HGF and 20 IU/ml of heparin. At this concentration, heparin does not itself stimulate angiogenesis, but instead enhances the angiogenic response induced by HGF. 52 The HGF/NRP1 interaction was disrupted by adding a blocking anti-NRP1 antibody to some plugs, whereas the control plugs contained a non For
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IgG group was similar to that of plugs from the PBS group ( Figure 6B) , demonstrating that the anti-NRP1 antibody had inhibited the vascularization induced by the angiogenic cocktail.
DISCUSSION
In endothelial cells, NRPs serve as coreceptors for members of the VEGF family, regulating VEGFR-dependent angiogenic events. The interaction of different VEGFs with neuropilins is thought to be mediated primarily by VEGF heparin-binding domains. 1 The core NRP1-binding region of VEGF-A 165 has been mapped to the carboxy-terminal 23 residues within the VEGF-A 165 heparin-binding site. 53 The structure of this region 54 is remarkably similar to the structure of the hairpin-loop region within N domain of HGF, 55 the only protein for which such a fold has been described. It therefore appeared possible, that VEGF-A 165 and HGF might interact, via their heparin-binding regions, with the same molecular partners, including
NRPs. Indeed, our binding studies showed that HGF interacted with both NRP1 and NRP2.
Our results also suggested that HGF interacts with NRPs via the HGF N-terminal domain.
Moreover, we found that the N-terminal domain of HGF competes with VEGF-A 165 for binding to NRP1, indicating that the binding sites for HGF and VEGF-A 165 on NRP1
probably overlap. The heparin-binding domain of VEGF-A 165 differs from that of HGF in surface charge distribution, suggesting that VEGF-A 165 and HGF interact with heparin in different ways. 54 We also found that lysozyme, a highly basic protein, did not displace VEGF-A 165 from its binding sites on NRP1, indicating that the VEGF-A 165 /NRP1 interaction is not simply charge-dependent. These observations are not consistent with NRP1 behaving simply as a heparin mimetic. 29 Instead, they suggest that NRP1 is involved in a specific interaction that may be strengthened by heparin or proteoglycans.
only.
For For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From production and biological activity of two blocking monoclonal antibodies raised against the semaphorin-and VEGF-binding sites of NRP1. 27 Both antibodies inhibit the VEGF-A 165 -induced migration and sprouting of endothelial cells and vascular remodeling. The antibody blocking the VEGF-binding site on NRP1 had a small effect on VEGFR-2 phosphorylation, p38 kinase activation and HUVEC proliferation, with no effect on ERK1/2 and Akt activity.
The authors suggested that NRP1 might act independently of the VEGFR-2 receptor, and might principally control endothelial cell migration. Another study, analyzing the biological activity of a bicyclic peptide NRP1 antagonist, EG3287, showed that disruption of the VEGF/NRP1 interaction inhibits the VEGF-A 165 -induced activation of ERK1/2 and Akt, but has no effect on endothelial cell proliferation. 17 Finally, using RNA interference-mediated silencing of NRP1, Murga et al demonstrated that NRP1 is necessary for both VEGF-induced ERK1/2 phosphorylation and proliferation in HUVEC. 49 These various results suggest that the amplitude and spectrum of effects induced by NRP inhibition may vary with cellular context.
Our findings provide new insight into the molecular mechanisms underlying the cooperation between VEGF-A and HGF in induction of the angiogenic response. 43, 59 They suggest that these two cytokines act through common coreceptors − the NRPs. NRPs, given their multiple interactions with various partners, are probably part of multicomponent complexes containing other receptors, effectors, adhesion molecules and adaptor proteins.
These complexes, known as signalosomes, are currently believed to be the principal signaltransducing elements regulating receptor activation, endocytosis, recycling, degradation, and the recruitment of downstream effectors. 60 NRPs may have a general scaffold function in signalosome formation. By independent recruitment of NRPs, and activating associated molecules, VEGF and HGF may be involved in modulating signalosome functioning, thereby influencing signaling through unrelated receptors.
In conclusion, we demonstrate that, in addition to VEGF-A 165 , both NRP1 and NRP2 bind to and enhance the activity of HGF, a powerful proangiogenic cytokine. Recent studies have indicated that other heparin-binding proangiogenic cytokines may also interact with NRPs. 29 Thus, the role of NRPs in vascular biology may be more extensive than simple regulation of the activity of VEGFs. Both NRP1 and NRP2 are up-regulated during pathological angiogenesis, 4 a context in which NRPs probably act as multifunctional enhancers coordinating the action of diverse proangiogenic stimuli. The pharmacological targeting of NRPs is therefore a promising therapeutic approach for the treatment of angiogenesis-associated disorders.
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